- Details
- Description
-
Packaging Size1Bottle/Box
-
Strength40mg/1ml
-
CompositonToripalimab (特瑞普利单抗)
-
TreatmentNasopharyngeal Carcinoma (NPC)
-
FormInjection
-
BrandLoqtorzi (拓益, ZYTORVI)
-
Quantity Unit240mg*6ml/Bottle/Box
-
ManufacturerJunshi Biosciences,China
About Toripalimab
Toripalimab-tpzi is a next generation anti-PD-1 monoclonal antibody that blocks PD-L1 binding to the PD-1 receptor at a unique site with high affinity and activates antitumor immunity demonstrating improvement in the overall survival of cancer patients in several tumor types.
- Toripalimab sold under the brand name LOQTORZI® in Europe.
- Toripalimab sold under the brand name ZYTORVI® in India.
- Toripalimab sold under the brand name 拓益® in china.
Approved
On October 27, 2023
The FDA approved toripalimab-tpzi (LOQTORZ, Coherus BioSciences, Inc.) with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma (NPC).
FDA also approved toripalimab-tpzi as a single agent for adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.
September 24, 2024
Shanghai -- On September 24, 2024, Beijing time, Junshi Biosciences (1877.HK, 688180.SH) announced that the company's independently developed anti-PD-1 monoclonal antibody drug Toripalimab (European trade name: LOQTORZI®) has recently been approved by the European Commission (EC) for the treatment of two indications:
- Toripalimab combined with cisplatin and gemcitabine is used for the first-line treatment of adult patients with recurrent, inoperable or radiotherapy-intolerant, or metastatic nasopharyngeal carcinoma (NPC);
- Toripalimab combined with cisplatin and paclitaxel is used for the first-line treatment of adult patients with unresectable advanced/recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
